AR095541A1 - Muteínas de interleucina-2 (il-2) para la expansión de células t reguladoras - Google Patents
Muteínas de interleucina-2 (il-2) para la expansión de células t reguladorasInfo
- Publication number
- AR095541A1 AR095541A1 ARP140101154A ARP140101154A AR095541A1 AR 095541 A1 AR095541 A1 AR 095541A1 AR P140101154 A ARP140101154 A AR P140101154A AR P140101154 A ARP140101154 A AR P140101154A AR 095541 A1 AR095541 A1 AR 095541A1
- Authority
- AR
- Argentina
- Prior art keywords
- mutein
- cells
- regulatory
- human
- interleucine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
- C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361784669P | 2013-03-14 | 2013-03-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR095541A1 true AR095541A1 (es) | 2015-10-21 |
Family
ID=50680166
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP140101154A AR095541A1 (es) | 2013-03-14 | 2014-03-14 | Muteínas de interleucina-2 (il-2) para la expansión de células t reguladoras |
Country Status (40)
Families Citing this family (140)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA201892619A1 (ru) | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
| US20190202898A9 (en) * | 2012-04-03 | 2019-07-04 | Novelmed Therapeutics, Inc. | AGLYCOSYLATED ANTI-C3b ANTIBODIES AND USES THEREOF |
| KR101520534B1 (ko) | 2012-05-07 | 2015-05-21 | 고려대학교 산학협력단 | 말초혈액단핵구 유래 자연 살해세포의 유도 및 증식 방법 |
| US20140044675A1 (en) | 2012-08-10 | 2014-02-13 | Roche Glycart Ag | Interleukin-2 fusion proteins and uses thereof |
| US9926366B2 (en) * | 2012-10-04 | 2018-03-27 | Novelmed Therapeutics, Inc. | Methods of treating a hemolytic disorder comprising administering anti-properdin antibodies |
| US9580486B2 (en) * | 2013-03-14 | 2017-02-28 | Amgen Inc. | Interleukin-2 muteins for the expansion of T-regulatory cells |
| KR102215405B1 (ko) | 2013-03-15 | 2021-02-10 | 암젠 인크 | 인간 pac1 항체 |
| PL2970422T3 (pl) | 2013-03-15 | 2018-09-28 | F.Hoffmann-La Roche Ag | Polipeptydy IL-22 i białka fuzyjne IL-22 Fc i sposoby zastosowania |
| PT3102595T (pt) | 2014-02-06 | 2019-01-11 | Hoffmann La Roche | Proteínas de fusão de interleucina-2 e suas utilizações |
| KR102493543B1 (ko) | 2014-07-21 | 2023-01-30 | 데리니아, 인크. | 자가면역 질환의 치료를 위한 조절 t 세포를 선택적으로 활성화시키는 분자 |
| JP6640834B2 (ja) | 2014-08-11 | 2020-02-05 | デリニア， インコーポレイテッド | 自己免疫疾患の処置のために調節性ｔ細胞を選択的に活性化させる改変ｉｌ−２変異体 |
| UY36302A (es) | 2014-09-15 | 2016-04-29 | Amgen Inc | Proteína de unión a antígenos, bi-específicos del receptor anti-cgrp/receptor pac1 y usos de las mismas |
| WO2016100375A2 (en) * | 2014-12-15 | 2016-06-23 | Washington University | Compositions and methods for targeted cytokine delivery |
| AU2016246152A1 (en) * | 2015-04-10 | 2017-11-02 | Amgen Inc. | Interleukin-2 muteins for the expansion of T-regulatory cells |
| IL304950A (en) | 2015-04-10 | 2023-10-01 | Amgen Inc | Interleukin for the expansion of myotonic control T-2 cells |
| TWI829617B (zh) | 2015-07-31 | 2024-01-21 | 德商安美基研究（慕尼黑）公司 | Ｆｌｔ３及ｃｄ３抗體構築體 |
| EA039859B1 (ru) * | 2015-07-31 | 2022-03-21 | Эмджен Рисерч (Мюник) Гмбх | Биспецифические конструкты антител, связывающие egfrviii и cd3 |
| TWI744242B (zh) | 2015-07-31 | 2021-11-01 | 德商安美基研究（慕尼黑）公司 | Egfrviii及cd3抗體構築體 |
| TWI796283B (zh) | 2015-07-31 | 2023-03-21 | 德商安美基研究（慕尼黑）公司 | Ｍｓｌｎ及ｃｄ３抗體構築體 |
| EP3353288A1 (en) | 2015-09-22 | 2018-08-01 | H. Hoffnabb-La Roche Ag | Expression of fc-containing proteins |
| US10822408B2 (en) | 2015-12-15 | 2020-11-03 | Amgen Inc. | PACAP antibodies and uses thereof |
| CR20180365A (es) | 2015-12-16 | 2018-09-28 | Amgen Inc | PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS |
| US20170204154A1 (en) | 2016-01-20 | 2017-07-20 | Delinia, Inc. | Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases |
| UA126657C2 (uk) * | 2016-02-03 | 2023-01-11 | Емджен Рісерч (Мюнік) Ґмбг | ОДНОЛАНЦЮГОВА КОНСТРУКЦІЯ АНТИТІЛА ДО BCMA І CD3<font face="Symbol">e</font> |
| AR107582A1 (es) * | 2016-02-03 | 2018-05-16 | Amgen Res Munich Gmbh | Constructos de anticuerpo biespecíficos para psma y cd3 que se ligan a células t |
| US11053293B2 (en) | 2016-02-05 | 2021-07-06 | Washington University | Compositions and methods for targeted cytokine delivery |
| CN107287273B (zh) * | 2016-03-31 | 2021-03-09 | 复旦大学附属妇产科医院 | 表达Tim-3的外周血NK细胞在制备自然流产生物标记物中的用途 |
| WO2017180587A2 (en) | 2016-04-11 | 2017-10-19 | Obsidian Therapeutics, Inc. | Regulated biocircuit systems |
| KR20240115933A (ko) * | 2016-05-04 | 2024-07-26 | 암젠 인크 | T-조절 세포의 증식을 위한 인터류킨-2 뮤테인 |
| IL263874B2 (en) | 2016-06-22 | 2025-02-01 | David Klatzmann | Genetically modified T lymphocytes |
| WO2018027025A1 (en) * | 2016-08-03 | 2018-02-08 | Oncomed Pharmaceuticals, Inc. | Cd40-binding agents and uses thereof |
| KR101928981B1 (ko) * | 2016-09-02 | 2018-12-13 | 고려대학교 산학협력단 | 항체 중쇄불변부위 이종이중체 (heterodimeric Fc)에 융합된 IL-21 (heterodimeric Fc-fused IL-21) 및 이를 포함하는 약제학적 조성물 |
| EP3538548A4 (en) | 2016-11-08 | 2020-08-19 | Delinia, Inc. | IL-2 VARIANTS FOR THE TREATMENT OF AUTOIMMUNE DISEASES |
| EP3551749B1 (en) | 2016-12-07 | 2023-09-27 | East Carolina University | Compositions and methods for in vitro cultivation and/or expansion of regulatory t cells |
| CN110913954A (zh) | 2017-03-03 | 2020-03-24 | 黑曜石疗法公司 | 免疫疗法的组合物和方法 |
| BR112019018915A2 (pt) | 2017-03-15 | 2020-04-14 | Pandion Therapeutics Inc | imunotolerância direcionada |
| JOP20190248A1 (ar) | 2017-04-21 | 2019-10-20 | Amgen Inc | بروتينات ربط مولد ضد trem2 واستخداماته |
| JOP20190271A1 (ar) | 2017-05-24 | 2019-11-21 | Novartis Ag | بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة |
| AU2018273914A1 (en) * | 2017-05-24 | 2019-11-14 | Pandion Operations, Inc. | Targeted immunotolerance |
| KR102920712B1 (ko) | 2017-05-24 | 2026-01-30 | 노파르티스 아게 | 항체-사이토카인 생착된 단백질 및 암 치료에 있어서의 사용 방법 |
| KR102956517B1 (ko) | 2017-10-04 | 2026-04-23 | 암젠 인크 | 트랜스타이레틴 면역글로불린 융합 |
| KR102777151B1 (ko) | 2017-11-21 | 2025-03-05 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | 인터루킨-2의 부분 효능제 |
| US10174091B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
| EP3720871A4 (en) * | 2017-12-06 | 2021-09-15 | Pandion Operations, Inc. | TARGETED IMMUNOTOLERANCE |
| USRE50550E1 (en) | 2017-12-06 | 2025-08-26 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| KR20240115352A (ko) * | 2017-12-06 | 2024-07-25 | 팬디온 오퍼레이션스, 인코포레이티드 | Il-2 뮤테인 및 그 용도 |
| US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| JP7765181B2 (ja) * | 2017-12-19 | 2025-11-06 | ゼンコア インコーポレイテッド | 改変されたｉｌ－２ ｆｃ融合タンパク質 |
| CN111868079B (zh) | 2017-12-27 | 2025-06-17 | 协和麒麟株式会社 | Il-2变体 |
| JP7339262B2 (ja) | 2018-01-12 | 2023-09-05 | アムジェン インコーポレイテッド | Ｐａｃ１抗体及びその使用 |
| CN115710576A (zh) | 2018-02-01 | 2023-02-24 | Nkmax有限公司 | 产生天然杀伤细胞的方法和用于治疗癌症的组合物 |
| EP3752178A1 (en) | 2018-02-16 | 2020-12-23 | Iltoo Pharma | Use of interleukin 2 for treating sjögren's syndrome |
| PE20210313A1 (es) | 2018-03-28 | 2021-02-12 | Bristol Myers Squibb Co | Proteinas de fusion interleucina-2/receptor alfa de interleucina-2 y metodos de uso |
| WO2019235895A1 (ko) | 2018-06-07 | 2019-12-12 | 한국생명공학연구원 | 무당질 항체 생산용 형질전환 마우스 및 이로부터 생산된 무당질 항체의 용도 |
| US20220403001A1 (en) | 2018-06-12 | 2022-12-22 | Obsidian Therapeutics, Inc. | Pde5 derived regulatory constructs and methods of use in immunotherapy |
| AU2019288496B2 (en) | 2018-06-22 | 2024-11-21 | Cugene Inc. | Interleukin-2 variants and methods of uses thereof |
| MX2020014290A (es) | 2018-06-22 | 2021-08-05 | Cugene Inc | Farmacos bioactivables a base de citoquinas y métodos de usos de los mismos. |
| FI3817770T3 (fi) | 2018-07-02 | 2026-07-06 | Amgen Inc | Antigeeniä sitova anti-steap1-proteiini |
| WO2020007937A1 (en) | 2018-07-03 | 2020-01-09 | Iltoo Pharma | Use of interleukin-2 for treating systemic sclerosis |
| EP3836954B1 (en) | 2018-08-13 | 2025-05-07 | Iltoo Pharma | Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof |
| CN112105634B (zh) | 2018-09-21 | 2024-03-12 | 信达生物制药(苏州)有限公司 | 新型白介素2及其用途 |
| BR112021008486A2 (pt) * | 2018-11-01 | 2021-10-26 | Shandong New Time Pharmaceutical Co., Ltd | Anticorpo biespecífico e seu uso |
| US12350317B2 (en) | 2019-02-08 | 2025-07-08 | The Uab Research Foundation | Immunotherapy for the treatment and prevention of inflammatory bowel disease |
| US11254736B2 (en) | 2019-02-15 | 2022-02-22 | Integral Molecular, Inc. | Antibodies comprising a common light chain and uses thereof |
| CN119708241A (zh) | 2019-02-15 | 2025-03-28 | 因特格尔莫来库乐有限公司 | 密封蛋白6抗体及其用途 |
| CN119350468A (zh) * | 2019-03-29 | 2025-01-24 | 居里研究所 | 具有经修饰的生物活性的白介素-2变体 |
| CN111944036B (zh) * | 2019-05-14 | 2024-09-06 | 上海盖浦生物科技有限公司 | 一种增殖免疫细胞的突变体蛋白 |
| AU2020279240A1 (en) | 2019-05-20 | 2021-12-23 | Pandion Operations, Inc. | MAdCAM targeted immunotolerance |
| JP7778571B2 (ja) * | 2019-06-05 | 2025-12-02 | アッシャー バイオセラピューティクス， インコーポレイテッド | 免疫細胞機能をモジュレートするための変異体インターロイキン－２ポリペプチドと抗原結合分子の融合体 |
| US20220227888A1 (en) | 2019-06-07 | 2022-07-21 | Amgen Inc. | Bispecific binding constructs with selectively cleavable linkers |
| US20220324924A1 (en) | 2019-07-08 | 2022-10-13 | Amgen Inc. | Multispecific transthyretin immunoglobulin fusions |
| PH12022550165A1 (en) * | 2019-07-26 | 2023-05-08 | Visterra Inc | Interleukin-2 agents and uses thereof |
| EP4013775A1 (en) * | 2019-08-12 | 2022-06-22 | Askgene Pharma, Inc. | Il-2 fusion proteins that preferentially bind il-2ralpha |
| CN114555634B (zh) * | 2019-08-13 | 2025-01-10 | 美国安进公司 | 用于扩增调节性t细胞的白介素-2突变蛋白 |
| CN122060049A (zh) | 2019-09-13 | 2026-05-19 | 协和麒麟株式会社 | DcR3变体 |
| KR20220079590A (ko) | 2019-10-04 | 2022-06-13 | 티에이이 라이프 사이언시스 | Fc 돌연변이 및 부위-특이적인 접합 성질을 포함하는 항체 조성물 |
| MX2022005999A (es) * | 2019-11-20 | 2022-06-17 | Gi Cell Inc | Composicion de medio para el cultivo de linfocitos t y metodo para el cultivo de linfocitos t mediante el uso de la misma. |
| EP4048296A4 (en) * | 2019-11-29 | 2024-01-24 | Nkmax Co., Ltd. | Method of producing natural killer cells and compositions thereof |
| US20230036793A1 (en) | 2019-12-12 | 2023-02-02 | Iltoo Pharma | Interleukin 2 chimeric constructs |
| PE20221506A1 (es) * | 2019-12-17 | 2022-10-04 | Amgen Inc | Agonista doble de interleucina-2/receptor de tnf para uso en terapia |
| IL293978A (en) | 2019-12-20 | 2022-08-01 | Regeneron Pharma | New il2 agonists and methods of using them |
| CN115362168A (zh) | 2020-01-14 | 2022-11-18 | 辛德凯因股份有限公司 | 偏向化il2突变蛋白方法和组合物 |
| US11981715B2 (en) | 2020-02-21 | 2024-05-14 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a CD39 effector |
| BR112022017656A2 (pt) * | 2020-03-05 | 2022-10-18 | Univ Leland Stanford Junior | Variantes de il-2 concebidas |
| KR20220155316A (ko) * | 2020-03-19 | 2022-11-22 | 이노벤트 바이오로직스 (쑤저우) 컴퍼니, 리미티드 | 인터루킨-2 돌연변이 및 이의 용도 |
| WO2021185362A1 (zh) * | 2020-03-19 | 2021-09-23 | 信达生物制药(苏州)有限公司 | 白介素2突变体及其用途 |
| CA3171795A1 (en) * | 2020-04-06 | 2021-10-14 | Jintang DU | Modular synthetic receptors and methods of use |
| KR20230010251A (ko) | 2020-05-13 | 2023-01-18 | 보넘 테라퓨틱스, 인크. | 단백질 복합체의 조성물 및 그의 사용 방법 |
| CA3184351A1 (en) | 2020-06-04 | 2021-12-09 | Amgen Inc. | Bispecific binding constructs |
| US20230226203A1 (en) * | 2020-06-18 | 2023-07-20 | Proviva Therapeutics (Hong Kong) Limited | Activatable procytokines |
| CN112048018B (zh) * | 2020-08-31 | 2021-10-08 | 南方医科大学 | 一种嵌合t细胞生长因子及其应用 |
| CN116323653A (zh) * | 2020-09-04 | 2023-06-23 | 山东先声生物制药有限公司 | Il-2突变体及其应用 |
| US20240325495A1 (en) | 2020-10-29 | 2024-10-03 | Bristol-Myers Squibb Company | Fusion proteins for the treatment of disease |
| MX2023006573A (es) | 2020-12-03 | 2023-06-19 | Amgen Inc | Constructos de inmunoglobulina con multiples dominios de union. |
| CA3203977A1 (en) * | 2020-12-04 | 2022-06-09 | Visterra, Inc. | Methods of using interleukin-2 agents |
| IL303501A (en) * | 2020-12-10 | 2023-08-01 | Biocad Joint Stock Co | Immunogenic cytokine for activation of the human IL-10RA receptor and its use |
| TW202241932A (zh) * | 2020-12-23 | 2022-11-01 | 美商默沙東藥廠 | 用於治療自體免疫及發炎性疾病之il-2突變蛋白 |
| TW202304994A (zh) | 2021-04-02 | 2023-02-01 | 美商泰尼歐生物公司 | 促效性抗ｉｌ－２ｒ抗體及使用方法 |
| WO2022245500A1 (en) | 2021-05-19 | 2022-11-24 | Asher Biotherapeutics, Inc. | Il-21 polypeptides and targeted constructs |
| TW202306584A (zh) | 2021-05-27 | 2023-02-16 | 法商賽諾菲公司 | 具有對Fc受體之增強親和力及改良熱穩定性的Fc變體 |
| TW202317623A (zh) | 2021-06-14 | 2023-05-01 | 美商再生元醫藥公司 | 基於il2之治療劑及其使用方法 |
| EP4370139A4 (en) | 2021-07-14 | 2025-10-15 | Synthekine Inc | METHODS AND COMPOSITIONS FOR USE IN CELL THERAPY FOR NEOPLASTIC DISEASE |
| CA3227990A1 (en) * | 2021-08-06 | 2023-02-09 | Amgen Inc. | Isolation of therapeutic protein |
| CN113789346A (zh) * | 2021-08-25 | 2021-12-14 | 北京伟德杰生物科技有限公司 | 长效化重组人白细胞介素2融合蛋白及其制备方法和应用 |
| JP2024536840A (ja) * | 2021-09-26 | 2024-10-08 | ウーシー バイオロジクス アイルランド リミテッド | Ｉｌ－２バリアント及びその融合タンパク質 |
| CN118414160A (zh) | 2021-10-06 | 2024-07-30 | 艾尔图制药公司 | 对发炎组织具有靶向特异性的白介素2嵌合构建体 |
| WO2023064876A1 (en) | 2021-10-14 | 2023-04-20 | Teneobio, Inc. | Mesothelin binding proteins and uses thereof |
| CA3234995A1 (en) * | 2021-10-14 | 2023-04-20 | Latticon (Suzhou) Biopharmaceuticals Co., Ltd. | Novel antibody-cytokine fusion protein, preparation method therefor and use thereof |
| TW202333772A (zh) * | 2021-12-01 | 2023-09-01 | 美商威特拉公司 | 使用介白素-2藥劑之方法 |
| EP4476250A1 (en) | 2022-02-07 | 2024-12-18 | Vib Vzw | Engineered stabilizing aglycosylated fc-regions |
| WO2023164476A2 (en) * | 2022-02-22 | 2023-08-31 | The Regents Of The University Of Michigan | Compositions and methods for treating autoimmune disorders |
| CA3245295A1 (en) * | 2022-03-03 | 2025-06-13 | Hainan Simcere Pharmaceutical Co., Ltd. | Pharmaceutical Composition of Il2 Antibody-Mutant FC Block Fusion Protein and its Use |
| WO2023180527A1 (en) | 2022-03-25 | 2023-09-28 | Universität Zürich | Adenoviral mediated targeting of activated immune cells |
| WO2023227790A1 (en) | 2022-05-27 | 2023-11-30 | Sanofi | Natural killer (nk) cell engagers binding to nkp46 and bcma variants with fc-engineering |
| EP4561613A1 (en) | 2022-07-27 | 2025-06-04 | Teneobio, Inc. | Mesothelin binding proteins and uses thereof |
| AU2022477937A1 (en) | 2022-09-12 | 2025-04-10 | Assistance Publique - Hôpitaux De Paris | Interleukin-2 for use in treating autism spectrum disorder |
| EP4598958A1 (en) | 2022-10-05 | 2025-08-13 | Amgen Inc. | Combination therapies comprising t-cell redirecting therapies and agonistic anti-il-2r antibodies or fragments thereof |
| JP2026513101A (ja) | 2022-10-25 | 2026-04-23 | アブリンクス エン．ヴェー． | エフェクター機能が強化された糖鎖改変Ｆｃ変異ポリペプチド |
| CN120282987A (zh) | 2022-11-30 | 2025-07-08 | 因特格尔莫来库乐有限公司 | 包括双特异性型式的针对紧密连接蛋白6的抗体 |
| WO2024151515A2 (en) | 2023-01-09 | 2024-07-18 | Odyssey Therapeutics, Inc. | Anti-tnfr2 antigen-binding proteins and uses thereof |
| KR102917441B1 (ko) * | 2023-01-31 | 2026-01-27 | 주식회사 바이오앱 | 식물 발현 재조합 지카바이러스 외피단백질을 포함하는 백신 조성물 및 이의 제조방법 |
| AU2024226156A1 (en) | 2023-02-21 | 2025-08-28 | Teneobio, Inc. | C-kit binding proteins, chimeric antigen receptors, and uses thereof |
| AR133427A1 (es) | 2023-07-31 | 2025-09-24 | Sanofi Sa | Anticuerpos anti-gprc5d y composiciones |
| WO2025049858A1 (en) | 2023-09-01 | 2025-03-06 | Amgen Inc. | Molecules for treatment of cancer |
| WO2025096843A1 (en) | 2023-11-03 | 2025-05-08 | Amgen Inc. | Bispecific molecules |
| CN122122194A (zh) | 2023-11-03 | 2026-05-29 | 美国安进公司 | 成纤维细胞靶向分子 |
| EP4652282A4 (en) * | 2023-11-14 | 2026-06-24 | Cavalry Biosciences Inc | Compositions designed to target muscle cells and their uses |
| WO2025133290A1 (en) | 2023-12-21 | 2025-06-26 | Temper Bio | Protein for immune regulation |
| WO2025149633A1 (en) | 2024-01-12 | 2025-07-17 | Laigo Bio B.V. | Bispecific antigen binding proteins |
| TW202602940A (zh) | 2024-04-09 | 2026-01-16 | 美商安進公司 | 激動性抗ｉｌ－２ｒｂｇ重鏈抗體 |
| WO2025217240A1 (en) | 2024-04-10 | 2025-10-16 | Odyssey Therapeutics, Inc. | Anti-tnfr2 antigen-binding proteins and uses thereof |
| US20260028384A1 (en) | 2024-04-17 | 2026-01-29 | Visterra, Inc. | Use of il-2 variant for treating kidney transplant rejection |
| WO2025259515A2 (en) | 2024-06-11 | 2025-12-18 | Amgen Inc. | Combination treatment |
| WO2026006809A1 (en) | 2024-06-27 | 2026-01-02 | Odyssey Therapeutics, Inc. | Multispecific molecules binding tnfr2 and cd25 and uses thereof |
| TW202619716A (zh) | 2024-07-23 | 2026-05-16 | 法商賽諾菲公司 | Ｃｅｒｅｂｌｏｎ連接酶調節劑與ｂｃｍａ ｎｋ細胞銜接子的組合療法 |
| EP4707296A1 (en) | 2024-09-05 | 2026-03-11 | Egle Therapeutics | Interleukin-2 variants with modified biological activity |
| EP4707295A1 (en) | 2024-09-05 | 2026-03-11 | Egle Therapeutics | Interleukin-2 variants with modified biological activity |
| US20260109746A1 (en) | 2024-10-22 | 2026-04-23 | Gilead Sciences, Inc. | Cd4-targeted il-15 molecules and methods of use |
| WO2026154422A1 (en) | 2025-01-17 | 2026-07-23 | Otsuka Pharmaceutical Company, Ltd. | Il-2-fc fusion protein for use in treating autoimmune diseases |
| WO2026159300A1 (en) | 2025-01-24 | 2026-07-30 | Iltoo Pharma | M3c65 antibody and derivatives thereof for targeting inflammation |
Family Cites Families (84)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4447A (en) | 1846-04-04 | Car- wheel | ||
| US233A (en) | 1837-06-14 | Improvement in plows | ||
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US3691016A (en) | 1970-04-17 | 1972-09-12 | Monsanto Co | Process for the preparation of insoluble enzymes |
| CA1023287A (en) | 1972-12-08 | 1977-12-27 | Boehringer Mannheim G.M.B.H. | Process for the preparation of carrier-bound proteins |
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4195128A (en) | 1976-05-03 | 1980-03-25 | Bayer Aktiengesellschaft | Polymeric carrier bound ligands |
| US4330440A (en) | 1977-02-08 | 1982-05-18 | Development Finance Corporation Of New Zealand | Activated matrix and method of activation |
| CA1093991A (en) | 1977-02-17 | 1981-01-20 | Hideo Hirohara | Enzyme immobilization with pullulan gel |
| US4229537A (en) | 1978-02-09 | 1980-10-21 | New York University | Preparation of trichloro-s-triazine activated supports for coupling ligands |
| US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
| US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| EP0088046B1 (de) | 1982-02-17 | 1987-12-09 | Ciba-Geigy Ag | Lipide in wässriger Phase |
| US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
| US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
| US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
| US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| EP0143949B1 (en) | 1983-11-01 | 1988-10-12 | TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION | Pharmaceutical composition containing urokinase |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
| EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
| JPS63502716A (ja) | 1986-03-07 | 1988-10-13 | マサチューセッツ・インステチュート・オブ・テクノロジー | 糖タンパク安定性の強化方法 |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| WO1988007054A1 (en) | 1987-03-18 | 1988-09-22 | Research Corporation Limited | Complement-binding peptide |
| US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
| US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
| US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
| US4965195A (en) | 1987-10-26 | 1990-10-23 | Immunex Corp. | Interleukin-7 |
| US4968607A (en) | 1987-11-25 | 1990-11-06 | Immunex Corporation | Interleukin-1 receptors |
| WO1990005183A1 (en) | 1988-10-31 | 1990-05-17 | Immunex Corporation | Interleukin-4 receptors |
| US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
| US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
| WO1991018982A1 (en) | 1990-06-05 | 1991-12-12 | Immunex Corporation | Type ii interleukin-1 receptors |
| CA2062582C (en) | 1991-03-27 | 1996-03-26 | Tse-Wen Chang | Methods and substances for recruiting therapeutic agents to solid tissues |
| US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| US6239328B1 (en) | 1992-10-05 | 2001-05-29 | North Carolina State University | Method for reducing expression variability of transgenes in plant cells |
| US6037525A (en) | 1996-08-01 | 2000-03-14 | North Carolina State University | Method for reducing expression variability of transgenes in plant cells |
| FR2752462B1 (fr) | 1996-08-14 | 1998-10-23 | Essilor Int | Procede d'incorporation d'additifs dans un article ophtalmique au moyen d'un fluide a l'etat supercritique |
| US6245974B1 (en) | 1997-08-06 | 2001-06-12 | North Carolina State University | Matrix attachment regions |
| US6955807B1 (en) | 1998-05-15 | 2005-10-18 | Bayer Pharmaceuticals Corporation | IL-2 selective agonists and antagonists |
| US6177612B1 (en) | 1998-07-31 | 2001-01-23 | Her Majesty The Queen In Right Of Canada, As Represented By The Department Of Agriculture And Agri-Food Canada | Matrix attachment regions |
| AU762382B2 (en) | 1998-09-29 | 2003-06-26 | Pioneer Hi-Bred International, Inc. | MAR/SAR elements flanking RSYN7-driven construct |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| KR100408844B1 (ko) | 2000-07-29 | 2003-12-06 | 한국산업기술평가원 | 동물세포 발현벡터 |
| SI1724284T1 (sl) * | 2000-12-07 | 2009-12-31 | Lilly Co Eli | Glp-1 fuzijski proteini |
| US7259010B2 (en) | 2000-12-15 | 2007-08-21 | Pangen Biotech Inc. | Expression vector for animal cell containing nuclear matrix attachment region of interferon beta |
| DK1395669T3 (da) | 2001-01-26 | 2009-11-16 | Selexis Sa | Matriks bindingsregioner og fremgangsmåder til anvendelse af disse |
| EP1454138B1 (en) | 2001-12-04 | 2012-01-18 | Merck Patent GmbH | Immunocytokines with modulated selectivity |
| US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| US20040132101A1 (en) * | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| ES2371072T3 (es) | 2003-06-12 | 2011-12-27 | Eli Lilly And Company | Proteínas de fusión análogas de glp-1. |
| WO2005007121A2 (en) | 2003-07-18 | 2005-01-27 | Massachusetts Institute Of Technology | Mutant interleukin-2(il-2) polypeptides |
| EP1694850B1 (en) | 2003-11-12 | 2011-06-29 | Schering Corporation | Plasmid system for multigene expression |
| KR20070003934A (ko) | 2004-03-05 | 2007-01-05 | 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 | 치료제의 환자 내약성을 예측하기 위한 시험관 내 테스트시스템 |
| CN1930300A (zh) * | 2004-03-05 | 2007-03-14 | 希龙公司 | 预测患者治疗药物耐受性的体外试验系统 |
| TR201808537T4 (tr) | 2004-09-23 | 2018-07-23 | Genentech Inc | Sistein değiştirilmiş antikorlar ve konjugatlar. |
| EP1877090B1 (en) * | 2005-05-06 | 2014-01-15 | Providence Health System | Trimeric ox40-immunoglobulin fusion protein and methods of use |
| JP2008543839A (ja) | 2005-06-14 | 2008-12-04 | アムジェン インコーポレーテッド | 自己緩衝タンパク質製剤 |
| CA2614766A1 (en) * | 2005-07-11 | 2007-01-18 | Macrogenics, Inc. | Methods of treating autoimmune disease using humanized anti-cd16a antibodies |
| GB0623539D0 (en) | 2006-11-24 | 2007-01-03 | Avidex Ltd | Polypeptides |
| CA2680792A1 (en) * | 2007-03-15 | 2008-09-18 | Biogen Idec Ma Inc. | Treatment of autoimmune disorders |
| US20090016935A1 (en) | 2007-07-09 | 2009-01-15 | Andrianov Alexander K | Coating formulations including polyphosphazene polyelectrolytes and biologically active agents and asperities coated with such formulations |
| US7695963B2 (en) | 2007-09-24 | 2010-04-13 | Cythera, Inc. | Methods for increasing definitive endoderm production |
| WO2009061853A2 (en) | 2007-11-05 | 2009-05-14 | Massachusetts Institute Of Technology | Mutant interleukin-2 (il-2) polypeptides |
| EP3663318A1 (en) | 2008-01-07 | 2020-06-10 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
| WO2010085495A1 (en) | 2009-01-21 | 2010-07-29 | Amgen Inc. | Compositions and methods of treating inflammatory and autoimmune diseases |
| JP2012515556A (ja) * | 2009-01-23 | 2012-07-12 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 低下したエフェクタ機能を有する安定化Ｆｃポリペプチドおよび使用方法 |
| EP2504360B1 (en) | 2009-11-23 | 2018-08-15 | Amgen Inc. | Monomeric antibody fc |
| KR20120107122A (ko) * | 2009-12-22 | 2012-09-28 | 노파르티스 아게 | 치료법에서 사용하기 위한 ４가 ｃｄ４７―항체 불변 영역 융합 단백질 |
| CN103443125B (zh) | 2010-11-30 | 2019-05-03 | 霍夫曼-拉罗奇有限公司 | 低亲和力血脑屏障受体抗体及其用途 |
| CN105440123B (zh) * | 2011-02-10 | 2020-10-09 | 罗切格利卡特公司 | 突变体白介素-2多肽 |
| WO2012125850A1 (en) | 2011-03-16 | 2012-09-20 | Amgen Inc. | Fc variants |
| EA201892619A1 (ru) * | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
| EP3539982B1 (en) | 2011-12-23 | 2025-02-19 | Pfizer Inc. | Engineered antibody constant regions for site-specific conjugation and methods and uses therefor |
| MX2014008961A (es) | 2012-02-06 | 2014-10-14 | Genentech Inc | Composiciones y metodos para utilizar inhibidores de csf1r. |
| WO2013177062A2 (en) | 2012-05-21 | 2013-11-28 | Genentech, Inc. | Methods for improving safety of blood-brain barrier transport |
| US9580486B2 (en) | 2013-03-14 | 2017-02-28 | Amgen Inc. | Interleukin-2 muteins for the expansion of T-regulatory cells |
| PL2970422T3 (pl) * | 2013-03-15 | 2018-09-28 | F.Hoffmann-La Roche Ag | Polipeptydy IL-22 i białka fuzyjne IL-22 Fc i sposoby zastosowania |
| US9300829B2 (en) | 2014-04-04 | 2016-03-29 | Canon Kabushiki Kaisha | Image reading apparatus and correction method thereof |
-
2014
- 2014-03-13 US US14/209,699 patent/US9580486B2/en active Active
- 2014-03-13 US US14/209,914 patent/US9546203B2/en active Active
- 2014-03-14 CA CA2905141A patent/CA2905141A1/en active Pending
- 2014-03-14 JP JP2016502936A patent/JP6480409B2/ja active Active
- 2014-03-14 WO PCT/US2014/028913 patent/WO2014153063A1/en not_active Ceased
- 2014-03-14 CA CA2906708A patent/CA2906708C/en active Active
- 2014-03-14 SI SI201431137T patent/SI2970441T1/sl unknown
- 2014-03-14 AU AU2014236316A patent/AU2014236316B2/en active Active
- 2014-03-14 EP EP14722463.8A patent/EP2970423B1/en active Active
- 2014-03-14 KR KR1020227022964A patent/KR20220101009A/ko not_active Ceased
- 2014-03-14 HR HRP20191075TT patent/HRP20191075T1/hr unknown
- 2014-03-14 UA UAA201509641A patent/UA119140C2/uk unknown
- 2014-03-14 SM SM20190415T patent/SMT201900415T1/it unknown
- 2014-03-14 CA CA3149348A patent/CA3149348C/en active Active
- 2014-03-14 TW TW109121895A patent/TWI784288B/zh active
- 2014-03-14 RS RS20190622A patent/RS58791B1/sr unknown
- 2014-03-14 PL PL14722463T patent/PL2970423T3/pl unknown
- 2014-03-14 LT LTEP14722463.8T patent/LT2970423T/lt unknown
- 2014-03-14 HR HRP20190970TT patent/HRP20190970T1/hr unknown
- 2014-03-14 PL PL14769541T patent/PL2970441T3/pl unknown
- 2014-03-14 EA EA201591731A patent/EA032863B1/ru not_active IP Right Cessation
- 2014-03-14 EP EP14769541.5A patent/EP2970441B1/en active Active
- 2014-03-14 CN CN201480027384.4A patent/CN105358570B/zh active Active
- 2014-03-14 SG SG11201507574VA patent/SG11201507574VA/en unknown
- 2014-03-14 DK DK14722463.8T patent/DK2970423T3/da active
- 2014-03-14 MA MA38477A patent/MA38477B1/fr unknown
- 2014-03-14 TR TR2019/10802T patent/TR201910802T4/tr unknown
- 2014-03-14 BR BR112015022440-7A patent/BR112015022440B1/pt active IP Right Grant
- 2014-03-14 SG SG11201507420UA patent/SG11201507420UA/en unknown
- 2014-03-14 CN CN201480014913.7A patent/CN105143253B/zh active Active
- 2014-03-14 JP JP2016502985A patent/JP6450365B2/ja active Active
- 2014-03-14 PT PT14769541T patent/PT2970441T/pt unknown
- 2014-03-14 PE PE2015002007A patent/PE20151763A1/es active IP Right Grant
- 2014-03-14 ME MEP-2019-148A patent/ME03482B/me unknown
- 2014-03-14 AU AU2014236281A patent/AU2014236281B2/en active Active
- 2014-03-14 DK DK14769541.5T patent/DK2970441T3/da active
- 2014-03-14 KR KR1020157027041A patent/KR102418771B1/ko active Active
- 2014-03-14 KR KR1020237037995A patent/KR20230157526A/ko not_active Ceased
- 2014-03-14 TW TW108117705A patent/TWI709572B/zh active
- 2014-03-14 UY UY0001035454A patent/UY35454A/es active IP Right Grant
- 2014-03-14 UY UY0001040090A patent/UY40090A/es active IP Right Grant
- 2014-03-14 HU HUE14722463 patent/HUE044321T2/hu unknown
- 2014-03-14 RS RS20190688A patent/RS58854B1/sr unknown
- 2014-03-14 CR CR20200004A patent/CR20200004A/es unknown
- 2014-03-14 PT PT14722463T patent/PT2970423T/pt unknown
- 2014-03-14 WO PCT/US2014/029111 patent/WO2014153111A2/en not_active Ceased
- 2014-03-14 ME MEP-2019-162A patent/ME03437B/me unknown
- 2014-03-14 SM SM20190301T patent/SMT201900301T1/it unknown
- 2014-03-14 MX MX2015012890A patent/MX372880B/es active IP Right Grant
- 2014-03-14 NZ NZ751148A patent/NZ751148A/en unknown
- 2014-03-14 HU HUE14769541A patent/HUE043488T2/hu unknown
- 2014-03-14 KR KR1020157027977A patent/KR102219124B1/ko active Active
- 2014-03-14 AP AP2015008737A patent/AP2015008737A0/xx unknown
- 2014-03-14 AR ARP140101154A patent/AR095541A1/es active IP Right Grant
- 2014-03-14 SI SI201431252T patent/SI2970423T1/sl unknown
- 2014-03-14 MX MX2015012912A patent/MX366854B/es active IP Right Grant
- 2014-03-14 TR TR2019/08362T patent/TR201908362T4/tr unknown
- 2014-03-14 MY MYPI2018002567A patent/MY202248A/en unknown
- 2014-03-14 MY MYPI2015002295A patent/MY172991A/en unknown
- 2014-03-14 ES ES14769541T patent/ES2720225T3/es active Active
- 2014-03-14 ES ES14722463T patent/ES2737598T3/es active Active
- 2014-03-14 EA EA201591766A patent/EA034326B1/ru not_active IP Right Cessation
- 2014-03-14 LT LTEP14769541.5T patent/LT2970441T/lt unknown
- 2014-03-14 TW TW103109295A patent/TWI687435B/zh active
- 2014-03-14 KR KR1020247040171A patent/KR20250002742A/ko active Pending
- 2014-03-16 JO JOP/2014/0119A patent/JO3796B1/ar active
-
2015
- 2015-09-09 IL IL241349A patent/IL241349B/en active IP Right Grant
- 2015-09-11 TN TN2015000416A patent/TN2015000416A1/en unknown
- 2015-09-11 PH PH12015502051A patent/PH12015502051B1/en unknown
- 2015-09-14 CL CL2015002669A patent/CL2015002669A1/es unknown
- 2015-09-14 CL CL2015002686A patent/CL2015002686A1/es unknown
- 2015-09-16 IL IL241622A patent/IL241622B/en active IP Right Grant
- 2015-10-09 MA MA49207A patent/MA49207B1/fr unknown
- 2015-10-14 CR CR20150557A patent/CR20150557A/es unknown
-
2016
- 2016-12-06 US US15/371,131 patent/US10093711B2/en active Active
-
2017
- 2017-01-17 US US15/408,281 patent/US9932380B2/en active Active
-
2018
- 2018-02-09 US US15/893,451 patent/US10562950B2/en active Active
- 2018-02-21 US US15/901,705 patent/US10829535B2/en active Active
- 2018-12-06 JP JP2018228769A patent/JP2019058182A/ja active Pending
-
2019
- 2019-05-24 CY CY20191100560T patent/CY1121767T1/el unknown
- 2019-07-22 CY CY20191100775T patent/CY1121823T1/el unknown
-
2020
- 2020-10-05 US US17/063,566 patent/US11976102B2/en active Active
- 2020-10-20 JP JP2020175778A patent/JP7227951B2/ja active Active
-
2023
- 2023-02-10 JP JP2023019024A patent/JP2023053148A/ja active Pending
-
2024
- 2024-04-04 US US18/627,094 patent/US20240327485A1/en active Pending
-
2025
- 2025-01-30 JP JP2025013617A patent/JP2025066162A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2657060T3 (es) | Fusoquinas que implican citoquinas con afinidades de unión por el receptor fuertemente reducidas | |
| PE20151763A1 (es) | Muteinas de interleucina-2 para la expansion de celulas t reguladoras | |
| CL2019003390A1 (es) | Proteínas de anticuerpo injertadas con citocina y métodos de uso en el tratamiento del cáncer | |
| CL2023001434A1 (es) | Muteína de il-2; proteína de fusión; ácido nucleico; vector; célula hospedera; métodos; uso | |
| SA517390134B1 (ar) | مركبات ميوتين إنترلوكين-2 لتمديد خلايا تائية منظمة | |
| MX2021008144A (es) | Composiciones para aumentar la media vida de un agente terapeutico en caninos y metodos de uso. | |
| AR090585A1 (es) | Anticuerpos anti-hla-b*27 y usos de estos | |
| AR099288A1 (es) | Proteínas de fusión de interleucina-10 | |
| NZ775714A (en) | Interleukin-2 muteins for the expansion of t-regulatory cells | |
| BR112023019138A2 (pt) | Proteína multiespecífica, composição farmacêutica, célula recombinante, método de preparação de uma composição de célula nk, composição de células nk, uso de uma proteína ou composição, métodos e uso | |
| CL2024003832A1 (es) | Anticuerpos que se unen a interleuquina 13 y métodos de uso | |
| CO6531481A2 (es) | Proteinas de enlace al antigeno il-23 humanas | |
| MY206284A (en) | Anti-cd63 antibodies, conjugates, and uses thereof | |
| UY38889A (es) | Inmunocitoquina que comprende un complejo de proteína heterodimérico basado en il-15/il-15r¿ y su uso | |
| PE20220706A1 (es) | Muteinas de interleucina-2 para la expansion de celulas t reguladoras | |
| ECSP088751A (es) | Anticuerpos contra la il-22 humana y usos para los mismos | |
| BR112018010937A2 (pt) | composições de anticorpos enxertados com citocina e métodos de uso para imunorregulação | |
| BR112023025331A2 (pt) | Proteína multiespecífica, composição farmacêutica, célula recombinante, ácido nucleico ou conjunto de ácidos nucleicos, uso de uma proteína ou composição, métodos ou uso | |
| CU20210041A7 (es) | Péptidos inmunogénicos con motivos de oxidorreductasa | |
| MX374817B (es) | Miembros de union para il-1 beta. | |
| BR112013005145A2 (pt) | anticorpos anti-cxcl13 e métodos para seu uso | |
| BR112017008525A2 (pt) | proteína de fusão isolada, e, métodos para tratamento ou alívio de um sintoma de uma doença ou distúrbio, para tratamento ou alívio de uma inflamação ou um sintoma de uma doença ou distúrbio inflamatório e para redução do risco de infecção em um indivíduo. | |
| BR112016011930A2 (pt) | combinações de peptídeos e seus usos em tratamento de alergia de ácaro de poeira | |
| MX2022008298A (es) | Anticuerpo para sesgar proporciones de sexos y metodos de uso del mismo. | |
| CO2017011431A2 (es) | Proteínas de fusión de receptor de factor de crecimiento epidermal variante iii - mesotelina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |